BioChaperone®
Technology for the development of next-generation formulations of peptides and proteins
BioChaperone® is the most advanced technology platform of Adocia. Adocia has conducted more than 30 clinical trials, from Phase 1 up to Phase 3, with products formulated with BioChaperone®.
BioChaperone® is a technology platform based on novel polymers, oligomers, and innovative small molecules. BioChaperone® compounds have no intrinsic biological activity. Pharmaceutical products developed using BioChaperone® technology are therefore designed to be more effective, more stable, easier to use for the patient and offer new applications.
Adocia has developed more than 800 BioChaperone® compounds, an impressive collection that continues to grow over time.
Two BioChaperone® candidates are the most advanced:
- BC 222 : designed to accelerate absorption
- BC 449 : designed to stabilize and combine peptides
BC 449 can spontaneously form a complex with other molecules, including therapeutic proteins. The complex is based on hydrophobic, electrostatic interactions or hydrogen bonds. BC 449 molecules interact reversibly and have non-degradative effects on the proteins. Complex is formed naturally after mixing in aqueous solution. The process does not require heating or the use of an organic solvent. The formulation-based approach presents the advantage of being easily produced at industrial scale.
Four key properties of the BC 449 technology have been demonstrated, via a complex formation with the protein or peptide:
- Increased solubility of proteins or peptides that are relatively insoluble at physiological pH
- Increased stability of proteins or peptides during storage
- Protection of proteins or peptides against enzymatic breakdown
- Stabilization of the activity of proteins or peptides in the presence of cells
